Pancreatic Cancer

Potential to extend survival and improve quality of life for pancreatic cancer patients.

Pancreatic cancer is among the deadliest types of cancer. While the incidence is comparatively low—it’s the twelfth most common type of cancer diagnosed worldwide1—mortality is high, with most patients succumbing to their disease within one year of diagnosis.2

Today, MRIdian is changing the paradigm for pancreatic cancer treatment.

  • MRIdian may be an option for patients who otherwise may not be offered treatment.3,4,5
  • Treatment may be completed in just five sessions of radiation therapy.3,4,5
  • Potential to extend survival, reduce toxicity and improve quality of life.3,4,5

Learn more about MRIdian treatment for pancreatic cancer today.

 

1Ferlay, J., et al. (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Retrieved August 30, 2019 from https://gco.iarc.fr/today
2United European Gastroenterology. (2018). Pancreatic cancer across Europe: Taking a united stand. Retrieved May 5, 2020 from https://www.spg. pt/wp content/uploads/2018/11/Pancreatic_Cancer_Report.pdf
3Rudra, S., Jiang, N., Rosenberg, S. A., Olsen, J. R., Roach, M. C., Wan, L., et al. (2019). Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Medicine, 8(5), 2123–2132. ​
4Herman, J. M., Chang, D. T., Goodman, K. A., Dholakia, A. S., Raman, S. P., Hacker-Prietz, A., et al. (2015). Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer, 121(7), 11281137. 
5de Gues, S. W. L., Eskander, M. F., Kasumova, G. G., Ng, S., C., Kent, T. S., Mancias, J. D., et al. (2017). Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer, 123(21), 4158-4167.

MRIdian Radiation Therapy for Pancreatic Cancer

Key Clinical Study

Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer

A retrospective study at five MRIdian centers showed that high-dose adaptive treatment improves overall survival and eliminates serious toxicity in patients with pancreatic cancer.

Ongoing Clinical Study

Stereotactic MRI-Guided On-Table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastrointestinal toxicity.

The goal of the proposed trial is to investigative in a controlled, prospective manner the robustness of this outcome, and to track quality of life over a 5-year trial period.

Eligible Participants
Patients with borderline resectable or inoperable locally advanced pancreatic cancer who are 18 years and older and meet the inclusion and exclusion criteria noted within the study description.

Trial Design
In this single-arm study, participants will receive radiation therapy using integrated magnetic resonance imaging (ViewRay’s MRIdian MR-Guided Radiation Therapy System) at a dose of 50 Gray in 5 fractions (treatment sessions). Fractions will be delivered at least twice per week and with at least 18 hours between treatments. Each participant will be aligned in the treatment system with MRI-guidance. On-table adaptive replanning will be used when clinically indicated. In all patients, real-time MR-imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam, as necessary.

Outcome Measures
The primary outcome measure of the study is grade 3 or higher gastrointestinal toxicity in the first 90 days after treatment. Secondary measures include overall survival at two years, distant progression-free survival at six months, and changes in patient-reported quality of life (pre-treatment to 12 months post-treatment and for longer periods up to five years).

For more information about trial design, inclusion and exclusion criteria, and trial locations visit https://clinicaltrials.gov/ct2/show/NCT03621644.

Videos Related To Pancreatic Cancer

Patient Story: Michael Vaquero, Pancreatic Cancer

August 13, 2020

ViewRay MRIdian for Prostate, Breast, and Pancreatic Cancer Treatment

October 22, 2019

MRI-Guided Radiation Therapy Panel

Radiation oncology experts from across the country gathered to discuss the potential of MRI-guided radiotherapy.

Miami Cancer Institute, Baptist Health South Florida

September 28, 2018

October 8, 2018

Scientific Presentations Related To Pancreatic Cancer

MR-Guided SBRT for Pancreas with On-Table Adaptation on MRIdian – MCI Experience

Michael Chuong, MD
Miami Cancer Institute, Baptist Health South Florida
ASTRO 2019

Dr. Chuong has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

SMART: Status Update on the First Prospective, Multi-Institutional Study on Ablative Pancreas SBRT

Parag Parikh, MD
Henry Ford Health System
ASTRO 2019

Dr. Parikh has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

 

Quantitative Radiomics of Daily 0.35T MR Images for Prediction of Tumor Response in Pancreas and Liver

John Chetley Ford, PhD
Sylvester Comprehensive Cancer Center, University of Miami Health System
ASTRO 2018

Dr. Ford has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

High Dose, On-Table, Adaptive Radiation Therapy for Pancreatic Cancer: Encouraging Early Results

Michael Bassetti, M.D., Ph.D. | Assistant Professor, Radiation Oncology
University of Wisconsin, Carbone Cancer Center
Miami Symposium (2018)

Dr. Bassetti has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Improving Pancreatic Cancer Survival by using MR Guided Adaptive Radiation

Parag Parikh, BSE, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine – St. Louis, MO
ASTRO 2017

Dr. Parikh has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

From Anatomical to Functional-based MR Guided Adaptive Radiotherapy: The UCLA Experience

Percy Lee, MD
UCLA Health, Jonsson Comprehensive Cancer Center – Los Angeles, CA
ASTRO 2017

Dr. Lee has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Clinical Experience with MR-guided Radiation Therapy for Pancreatic Tumors at VUmc

Anna Bruynzeel, MD, PhD
VUmc – Amsterdam, The Netherlands
ASTRO 2017

Dr. Bruynzeel has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.

Daily Adaptive Planning for Pancreatic Cancer

Frank Lagerwaard, MD
VUmc – Amsterdam, The Netherlands
ASTRO 2017

Dr. Lagerwaard has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Considerations and Challenges of MR Guided RT

John Bayouth, PhD
Carbone Cancer Center, University of Wisconsin – Madison, WI
ESTRO 37 (2018)

Dr. Bayouth has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

  Global Info

CUSTOMER LOGIN

Please log in to access the ViewRay Customer Portal. To request access, please click here. Request will be reviewed within 2 business days.

Existing Users Log In
   

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy

Accept